Inducing effect of feprazone on hepatic drug-metabolizing enzymes in man.
The inducing effect of feprazone, a pyrazolone anti-inflammatory agent, on hepatic drug-metabolizing enzymes has been studied in healthy volunteers. The ratio of 6 beta-hydroxycortisol (6 beta-OHF) to 17-hydroxycorticosteroids (17-OHCS) in urine, used as an indicator of oxidative drug-metabolizing enzyme activity, was increased up to 1.6-times the original level after 5 days of oral treatment with feprazone 300 mg/day. This indicates that feprazone induces hepatic drug-metabolising enzymes in man as does phenylbutazone.
D015065:17-Hydroxycorticosteroids / Q000378:metabolism; D000328:Adult; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D011298:Feprazone / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D006899:Mixed Function Oxygenases / Q000096:biosynthesis*; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D015065:17-Hydroxycorticosteroids; C001380:6 beta-hydroxycortisol; D011298:Feprazone; D006899:Mixed Function Oxygenases; D010653:Phenylbutazone; D006854:Hydrocortisone